Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma

Journal of Cutaneous Pathology

Volumn 25, Issue 5, 1998, Pages 244-251

  Miracco, Clelia ^a   Santopietro, Rosa ^a   Biagioli, Maurizio ^a   Lazzi, Stefano ^a   Nyongo, Aggrey ^b   Vatti, Rosella ^a   Luzi, Pietro ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Nairobi Hospital   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; MALIGNANT LENTIGO; MELANOMA; MITOSIS INDEX; ONCOGENE; ONCOGENE C MYC; PROTEIN EXPRESSION; TUMOR GROWTH;

CELL DEATH; CELL DIVISION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELANOMA; MITOTIC INDEX; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031779516     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1998.tb01728.x     Document Type: Article

References (41)

1. Arends MJ, Wyllie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 1991: 32: 223.
2. Bissonette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (London) 1992: 359: 552.
3. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (London) 1992: 359: 554.
4. Hofman B and Liebermann DA. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 1994: 9: 1807.
5. Miyashita T, Krajewski M, Wang H, et al. Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994: 9: 1799.
6. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995: 103: 300.
7. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994: 124: 1.
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science 1991: 253: 49.
9. Mooney EE, Ruis Peris JM, O'Neill A, Svveeney EC. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995: 48: 242.
10. Cerroni L, Soyer PH, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995: 17: 7.
11. Morales-Ducret CRJ, Van De Rijn M, LeBrun DP, Smaller BR. bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995: 131: 909.
12. Plettenberg A, Ballaun C, Pammer J, et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol 1995: 146: 651.
13. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995: 146: 643.
14. Van Den Oord J, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994: 145: 294.
15. Renz P, Pontén F, Nister M, Pontén J. Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer 1996: 69: 174.
16. Albino AP, Vidal MJ, McNutt NS, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994: 4: 35.
17. Florenes VA, Oyjord T, Holm R, et al. TP53 allele loss mutations and expression in malignant melanoma. Br J Cancer 1994: 69: 253.
18. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993: 53: 2235.
19. Saenz-Santamaria MC, McNutt NS, Bogdany JK, Shea CR. p53 expression is rare in cutaneous melanomas. Am J Dermatopathol 1995: 17: 344.
20. Sparrow LE, Soong R, Dawkins HJS, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995: 5: 93.
21. Strecht JR, Gatter KC, Rolfkider E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 1991: 51: 5976.
22. Yamamoto M, Takayashi H. Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch A Pathol Anat 1993: 422: 127.
23. Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takayashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res 1995: 287: 146.
24. Peris K, Cerroni L, Chimenti S, Soyer HP, Kerl H, Hofler H. Proto-oncogene expression in dermal nevi and melanomas. Arch Dermatol Res 1991: 283: 500.
25. Bergman R, Lurie M, Kerner H, Kilim S, Friedman-Birnbaum R. Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. J Cutan Pathol 1997: 24: 219.
26. Welch D, Bisi J, Miller B, Hendrix M. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 1991: 47: 227.
27. Korabiowska M, Brinck U, Mirecka J, Kellner S, Marx D, Schauer A. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. In vivo 1995: 9: 433.
28. Lever WF, Schaumburg-Lever G. Benign pigmemed lesions and malignant melanoma, in: Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, eds. Histopathology of the skin, 8th ed., Philadelphia: JB Lippincott, 1990, p 625.
29. Rigel DS, Sober AJ, Friedman RJ. Prognostic factors influencing survival in persons with cutaneous malignant melanoma. In: Friedman RJ, Rigel DS, Kopf AW, Harris MN, Baker D, eds. Cancer of the skin. Philadelphia: 1991, WB Saunders. p 198.
30. Van der Esch D, Cascinelli N, Preda F, Morabito A, Bufalino R. Stage I melanoma of the skin: evaluation and prognosis according to histologic characteristics. Cancer 1981: 48: 1668.
31. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993: 170: 1.
32. Ackerman AB. Malignant melanomas: a unifying concept. Am J Dermatopathol 1980: 2: 309.
33. Smolle J, Hofmann-Wellenhof R, Kofler R, Soyer HP, Kerl H. Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma. Anal Cell Pathol 1993: 5: 113.
34. Lu C, Kerbel RS. Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 1994: 6: 212.
35. Okuyama S, Yokota K, Yuki M. Cell proliferation and cell death (apoptosis) in epithelial tumors of the stomach. Nippon Shokakibyo Gakkai Zasshi 1995: 92: 130.
36. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 1994: 21: 393.
37. Loganzo Fjr, Nabeya Y, Maslak P, Albino AP. Stabilization of p53 protein is a critical response to UV radiation in human melanocytes: implications for melanoma development. Mol Cell Differ 1994: 2: 19.
38. Kock A, Schwartz T, Kirnbauer R, et al. Human keratinocytes are a sourge of tumor necrosis factor α: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 1990: 172: 1609.
39. Bystryn JC. Immunosurveillance and melanoma. J Invest Dermatol 1989: 92: 3185.
40. Vollmers HP, Dammrich J, Hensel F, et al. Differential expression of apoptosis receptors in diffuse and intestinal type stomach carcinoma. Cancer 1997: 79: 440.
41. Akslen LA, Morkve O. Expression of p53 protein in cutaneous melanoma. Int J Cancer 1992: 52: 13.